Over the past few years, the Health Care & Life Sciences and Innovative Technology Sectors have seen fewer deals, with companies and private equity firms alike reassessing where to spend money. But one portion of the industry is bucking this trend in a major way. Since 2018, licensing deals totaling over $60 billion have been signed regarding Antibody Drug Conjugates (ADCs), with 2023 alone having at least 18 deals. As a result, worldwide ADC sales are projected to reach $20-30 billion per year in the near future.

We welcome you to Antibody Conjugates Keep Growing: What You Need to Know. In this eBook, our authors answer your legal and business questions relating to the rapid expansion of ADCs and how you and your organization can understand ADCs, whether it’s pharmaceutical transactions, FDA/regulatory, intellectual property, clinical trial, or litigation concerns. This eBook is designed to provide the knowledge and insights needed to succeed in the ADC industry.

Table of Contents

1. Antibody Drug Conjugates: An FDA Perspective

2. Strategies For Patenting Antibody-Drug Conjugate Inventions

3. Deals and Licensing for Antibody-Drug Conjugates

4. Antibody-Drug Conjugate Litigation

5. Clinical Trial Issues for Antibody Drug Conjugates/Antibody Therapeutics